New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMGF (Mechano Growth Factor) vs Testagen

MGF (Mechano Growth Factor) vs Testagen

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
MGF (Mechano Growth Factor)
Anti-Aging & Longevity
Testagen
Summary
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
Testagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Gly) developed by Professor Vladimir Khavinson, tissue-specific for the testes. It supports Leydig cell function, normalization of testosterone biosynthesis, and spermatogenic activity. Testagen is used in men's health protocols for age-related testosterone decline, male fertility support, and testicular anti-aging.
Half-Life
Native MGF: minutes. PEG-MGF: ~3 days
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ, IM
SubQ, Oral
Research
Typical Dose
200–400 mcg
10 mg per day
Frequency
1–2 times per week
Daily for 10–30 days
Key Benefits
  • Activates muscle satellite cells for repair and growth
  • Accelerates recovery from muscle damage
  • Synergistic with IGF-1 LR3 (different mechanisms)
  • Promotes muscle hypertrophy specifically at exercised muscles
  • Faster recovery between training sessions
  • Potential for injury repair in connective tissue
  • Supports endogenous testosterone synthesis via Leydig cell normalization
  • Promotes spermatogenesis and sperm quality
  • Anti-aging effects on testicular tissue
  • May attenuate age-related testosterone decline
  • Mechanistically distinct from TRT — does not suppress HPG axis
  • Useful adjunct to Gonadorelin and Kisspeptin-10 in male hormonal protocols
  • Supports male fertility without exogenous hormone replacement
Side Effects
  • Muscle soreness (satellite cell activation)
  • Injection site irritation
  • Hypoglycemia risk (modest, less than IGF-1 LR3)
  • Generally well tolerated
  • Mild injection site reactions
  • No significant endocrine disruption reported at standard doses
Stacks With